The primary goal of these updated AUC is to assist clinicians in identifying clinical scenarios in which amyloid or tau PET may be useful for guiding the diagnosis and management of patients who have, or are at risk for, cognitive decline, while also highlighting scenarios in which PET scans are unlikely to provide clinically useful information. This evidence concerns the gene MAPT and Mental deterioration.